Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
34 hedge funds and large institutions have $15.5M invested in Forte Biosciences in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 1 closing their positions.
6,906% more capital inflows, than outflows
Capital inflows: $1.23M | Capital outflows: $17.5K
2,500% more call options, than puts
Call options by funds: $26K | Put options by funds: $1K
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
13% more funds holding
Funds holding: 30 → 34 (+4)
5.88% more ownership
Funds ownership: 46.03% → 51.91% (+5.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$71.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$8.62K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.82K |
| 4 |
Renaissance Technologies
New York
|
+$1.62K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$7.26K |
| 2 |
Jane Street
New York
|
-$7.13K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.3K |
| 4 |
Two Sigma Advisers
New York
|
-$1.23K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$349 |
FBRX Hedge Fund Activity: Q4 2023 in Review
34 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2023, worth a combined $15.5M — up 40% from $11.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new FBRX positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $71.7K. The largest seller was Goldman Sachs, cutting an estimated $7.26K.
- 34 institutional investors held Forte Biosciences (FBRX) as of Q4 2023, up from 30 in Q3 2023.
- Funds reported $15.5M of Forte Biosciences stock for Q4 2023, up 40% quarter-over-quarter.
- 5 funds opened new Forte Biosciences positions in Q4 2023 and 1 closed out, a net change of +4 holders.
- The largest Forte Biosciences buyer in Q4 2023 was Geode Capital Management, an estimated $71.7K added.
- The largest Forte Biosciences seller in Q4 2023 was Goldman Sachs, an estimated $7.26K sold.
Based on aggregated 13F filings for Q4 2023.